Tibial Nerve Stimulation for Pediatric Spina Bifida Neurogenic Bladder

Not Applicable

Not yet recruiting

• Conditions: Neurogenic Bladder Due to Spina Bifida

• Registration Number: NCT07136688
• Lead Sponsor: The University of Texas Health Science Center, Houston

Brief Summary

The purpose of this study is to determine the safety, feasibility, and compliance of a daily home transcutaneous tibial nerve stimulation (tTNS) protocol in children with chronic neurogenic bladder (NB) provided by self or caregiver for 4 weeks and to estimate the efficacy of tTNS

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-08
• Study First Submitted: 2025-08-14
• Study First Submitted QC: 2025-08-14
• Last Update Submitted: 2025-08-14
• Study Start: 2025-08-18
• Study First Posted: 2025-08-22
• Last Update Posted: 2025-08-22
• Primary Completion: 2027-04-11
• Study Completion: 2027-08-11

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• chronic neurogenic bladder
• Spina Bifida diagnosis
• Use of overactive bladder medication(s)
• Stable bladder medications for ≥ 3 months

Exclusion Criteria

• Progressive SCI (ex: transverse myelitis, polio, etc.)
• Other lower urinary tract pathology or surgery
• 2+ pitting edema in the legs that does not resolve
• Known peripheral neuropathy or injury to the path of the tibial nerve
• Cancer in the tibial nerve pathway and/or lower urinary tract
• Inability to elicit the motor response with electric stimulation
• Inability to complete the tTNS proficiency checklist (guardians)
• Non-English speaking (guardians)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Safety as assessed by the number of adverse events	from start of trial to end of trial (4 weeks after start)
Feasibility as assessed by the satisfaction surveys	end of study (4 weeks after baseline)	This is an 8 item questionnaire and each is scored from 1(strongly disagree) to 5(strongly agree) for a maximum score of 40, higher score indicating greater satisfaction .
Compliance of tTNS usage as assessed by the percent of sessions where toe flexion was elicited	from start of trial to end of trial (4 weeks after start)	This will be reported in the TTNS log
Compliance of tTNS usage as assessed by the average current where toe flexion was elicited	from start of trial to end of trial (4 weeks after start)	This will be reported in the TTNS log
Compliance of tTNS usage as assessed by percentage of sessions that bladder medications were taken	from start of trial to end of trial (4 weeks after start)	This will be reported in the TTNS log
Satisfaction as assessed by the survey	end of study (4 weeks after baseline)	This will measure the likelihood of tTNS preference over anticholinergic medication use; This is an 8 item questionnaire and each is scored from 1(strongly disagree) to 5(strongly agree) for a maximum score of 40, higher score indicating greater satisfaction .

Secondary Outcome Measures

Name	Time	Method
Percentage of participants that are able to reduce their overactive bladder (OAB) medications	end of study (4 weeks after baseline)
percent dose reduction (mg ) achieved	end of study (4 weeks after baseline)
Change in maximum detrusor pressure (Max Pdet (cmH20)) as assessed by the Urodynamic study (UDS)	week 0, week 4
Presence of Detrusor overactivity (DO) as assessed by the Urodynamic study (UDS)	Week 4
Change in maximum volume (mL) that bladder can hold before voiding or discomfort as assessed by the Urodynamic study (UDS)	Week 0, Week 4
Presence of bladder leak as assessed by the Urodynamic study (UDS)	Week 4
Change in bladder sensation as assessed by the Urodynamic study (UDS)	Week 0, Week 4	volume infused (mL) at 1) time of reported first sensation of filling, 2) time of reported urgency/desire to void, \& 3) time of reported discomfort
Change in detrusor compliance as assessed by the Urodynamic study (UDS)	Week 0, Week 4	reported as change in bladder volume divided by change in bladder pressure.
Number of incontinence episodes as reported in the voiding diary	from start of trial to end of trial (4 weeks after start)
Frequency of catheterization as reported in the voiding diary	from start of trial to end of trial (4 weeks after start)
Volumes of catheterization as reported in the voiding diary	from start of trial to end of trial (4 weeks after start)
Change in bladder symptoms as assessed by the Neurogenic Bladder Symptom Score (NBSS)	Week 0, Week 4	This is a 24 item questionnaire that is scored from 0 (no symptoms) to 4 (worst symptoms), maximum score of 96 with higher values indicating greater symptom burden
Change in bowel function as assessed by the Neurogenic Bowel Dysfunction Score (NBDS)	Week 0, Week 4	This is a 10 item questionnaire that is scored from 0 (very minor ) to greater than or equal to 14(severe), maximum score range of 0-47 with higher scores indicating worse outcome
Change in general physical and mental health status as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire for Global Health	Week 0, Week 4	This is a 10 item questionnaire. The measure yields two standardized summary scores: Global Physical Health (GPH) and Global Mental Health (GMH).Each summary score is calculated based on 4 items from the questionnaire and is converted to a T-score using the PROMIS scoring manual. T-scores have a mean of 50 and standard deviation of 10, based on the U.S. general population. Higher T-scores indicate better health.

Trial Locations

Locations (1)

The University of Texas Health Science Center and Houston; 🇺🇸 Houston, Texas, United States